Clinical Trial Update: A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TQB2450 in combination with intensity-modulated radiotherapy for patients with inoperable locally recurrent nasopharyngeal carcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED